Evercore ISI Group Maintains Outperform on Madrigal Pharmaceuticals, Lowers Price Target to $649
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Evercore ISI Group analyst Liisa Bayko maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform and lowers the price target from $652 to $649.
Evercore ISI Group analyst Liisa Bayko maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform and lowers the price target from $652 to $649.